10-Q: 23andMe Reports Q3 2025 Results, Announces Strategic Review Amidst Going Concern Uncertainty

23andMe reports a mixed Q3 with revenue increase driven by a GSK agreement, but expresses substantial doubt about its ability to continue as a going concern.

Summary

• 23andMe's Q3 2025 revenue increased by 35% year-over-year to $60.3 million, driven by a $19.3 million non-recurring revenue recognition from a GSK agreement.
• Consumer revenue decreased due to lower PGS kit sales and telehealth revenue, partially offset by growth in PGS membership services.
• The company is implementing cost-cutting measures, including a 40% workforce reduction and ceasing operations in the Therapeutics segment.
• 23andMe is exploring strategic alternatives, including a potential sale of the company.
• The company has substantial doubt about its ability to continue as a going concern due to significant operating losses and negative cash flows.
• The company settled a class action lawsuit related to a cyber incident for $30 million, pending final court approval.
• The company has regained compliance with Nasdaq listing requirements after a reverse stock split and the appointment of independent directors.
• The company is working to remediate a material weakness in internal control over financial reporting.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the going concern warning and net losses, despite some positive revenue growth driven by a one-off event.

Positives

• Revenue increased by 35% year-over-year in Q3 2025.
• The company has regained compliance with Nasdaq listing requirements.
• The company is implementing cost-cutting measures to improve its financial position.

Negatives

• The company has substantial doubt about its ability to continue as a going concern.
• Consumer revenue decreased due to lower PGS kit sales and telehealth revenue.
• The company reported a net loss of $53.0 million for Q3 2025.
• The company is working to remediate a material weakness in internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is contingent upon raising additional capital and implementing cost-cutting measures.
• The company may not be able to obtain additional financing on acceptable terms or at all.
• The company's strategic restructuring may not result in anticipated savings.
• The company's business, results of operations, and financial condition could be materially and adversely affected if it is unable to raise additional capital.
• The company is subject to risks related to the Cyber Incident and ongoing litigation and investigations.

Future Outlook

The company expects PGS revenues to fluctuate in the near-term and to grow in the long-term, as it continues to evolve its product offerings across kit sales and its membership service, and introduce new products or features that enhance or add value for customers and members.

Management Comments

• The company is attempting to raise additional capital.
• The company is working to implement cost-cutting measures, including further reducing operating expenses, negotiating terminations of the company's long-term real estate leases, and attempting to reach a settlement covering all U.S. customers affected by the Cyber Incident as well as to resolve non-U.S. litigation and ongoing investigations from various governmental agencies arising from the Cyber Incident.

Industry Context

The telehealth market is competitive, with many participants including new entrants and traditional healthcare systems offering virtual care.

Comparison to Industry Standards

• The document does not provide enough information to compare 23andMe's results to specific industry standards or comparable companies.
• Without detailed industry benchmarks for revenue growth, customer acquisition cost, or profitability metrics, it is difficult to assess 23andMe's performance relative to its peers.

Legal Proceedings

• The company settled a class action lawsuit related to a cyber incident for $30 million, pending final court approval.
• The company is responding to inquiries from various governmental officials and agencies related to the Cyber Incident.

Related Party Transactions

• The company has a research services agreement with the Troper Wojcicki Foundation, which is affiliated with the company's CEO.
• The company has transactions with GlaxoSmithKline (GSK), which has a significant voting interest in the company.

Stakeholder Impact

• Shareholders face uncertainty due to the going concern warning and exploration of strategic alternatives.
• Employees have been impacted by the workforce reduction.
• Customers may be affected by changes in product offerings and services.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company will continue to explore strategic alternatives, including a potential sale of the company.
• The company will continue to implement cost-cutting measures.
• The company will work to remediate the material weakness in internal control over financial reporting.

Key Dates